The North America Nifedipine market size is expected to reach a valuation of USD 661.21 million by 2030, growing at a CAGR of 8.95 % during the forecast period (2022–2030).
Nifedipine is a calcium channel blocker that stops calcium from passing through the walls of the arteries. High blood pressure, arrhythmias, and angina are all treated with nifedipine. Other therapeutic uses include ryanoids syndrome, cephalalgia, and so on. An increase in the senior population, healthcare spending, the incidence of chronic illnesses such as heart failure, arrhythmias, and hypertension, and healthcare awareness are all driving the market. Government regulations and negative pharmacological effects such as hypotension, stomach ulcers, and congestive heart failure, on the other hand, hinder market expansion. R&D operations are likely to yield new development opportunities. Other dihydropyridine calcium channel blockers, such as nitrendipine and nisoldipine, are used to address HBP disorders. Premature labour has been more common in recent years, causing a surge in demand for the aforementioned medications. Tocolytics are used to treat premature labour by preventing muscle contractions. Similarly, nifedipine protects preemies from health problems that arise as a result of their early delivery. Nifedipine market is valued at USD 856.66 million in 2020, and is predicted to reach USD 1,792.36 million by 2029, representing an 8.49% compound annual growth rate (CAGR).
The largest revenue share belongs to the North American nifedipine market, which is predicted to rise throughout the forecast period. The rise of chronic long-term illnesses as a significant health issue around the world is predicted to fuel growth. Furthermore, following COVID-19, the use of calcium channel blocking medicines such as Nicardipine, Norvasc, and Procardia has grown, resulting in an increase in acute and chronic health issues in the region.
Nifedipine controlled-release tablets and nifedipine extended-action tablets are the two types of nifedipine pills. Nifedipine controlled-release tablets had the most market share in 2021. This significant increase can be ascribed to rising rates of hypertension and heart failure, the use of cutting-edge technology in pharmaceutical research, more funding from the government and international organisations, and increased public knowledge about the importance of preventative treatment.
The part is separated into primary pulmonary hypertension, heart failure, Raynaud's syndrome, cephalalgia, and others based on the application. In 2021, the most common cause of pulmonary hypertension was primary pulmonary hypertension. Obesity, poor dietary habits, excessive junk food intake, a lack of exercise, a rise in the younger generation's smoking and alcohol usage, and stress are all contributing factors. This category is expected to be driven by expanding government and private sector activities and firm programmes for the development of improved pharmaceuticals to treat hypertension and diabetes.
The North America nifedipine market is divided into hospital pharmacies, retail pharmacies, and other distribution channels. In 2020, the hospital pharmacies segment dominated the region’s market, and it is expected to rise at a faster CAGR throughout the forecast period.
By 2030, the North America Nifedipine market is estimated to be worth USD 661.21 million, increasing at a CAGR of 8.95% over the forecast period (2022–2030). The North America market has the greatest revenue share, which is expected to grow during the projected period. Growth is expected to be drive by the emergence of chronic long-term illnesses as a major health issue around the world. Furthermore, as a result of COVID-19, the use of calcium channel blocking medications like Nicardipine, Norvasc, and Procardia has increased, resulting in a rise in acute and chronic health difficulties in the region.
Obesity also affects 332,915,000 adults in the United States, or 36.20%. People's unhealthy lifestyles put them at risk for diseases like high blood pressure, chest pains, and heart attacks, among others. As a result, overall drug consumption is rising, resulting in increased demand for Nifedipine. In 2021, the United States overtook every other country in terms of obesity rates. Because 36.20% of persons in the United States are overweight, calcium channel blockers are the most commonly prescribed drugs.
Ischemic heart disease was diagnosed in around 158,700 (6.1 per 1,000) Canadian individuals aged 20 and up. A total of 63,200 adults (2.3 per 1,000) experienced their first heart attack. In a given year, Canadian people with ischemic heart disease (IHD) were three times more likely than those without the illness to die of any cause. A total of 92,900 (5.2 per 1,000) Canadian adults aged 40 and up were diagnosed with heart failure for the first time and hence demand for Nifedipine in Canada is anticipated to accelerate during the forecast period.
Coronary heart disease has grown by 90% in Mexico since 1970. Heart disease was the second leading reason for death in recent years, with 59.7% of men and 47.9% of women dying from it. In Mexico, fatalities from heart disease accounted for more than 17% recently and this is the significant reason for the growth in demand for Nifedipine in the region.
Some of the major players in the North America Region (having significant market shares) are listed below:
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|